Orbactiv

NDC 70842-140 · Melinta Therapeutics, LLC

Generic nameoritavancin

Dosage formINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

RouteINTRAVENOUS

Active ingredient(s)ORITAVANCIN

Strength400 mg/1

Pharmacologic classCytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Lipoglycopeptide Antibacterial [EPC], Lipoglycopeptides [CS]

Marketing categoryNDA

Packages

70842-140-03 — 3 VIAL, GLASS in 1 CARTON (70842-140-03) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS (70842-140-01)

Billed under HCPCS

J2407 — Injection, oritavancin (orbactiv), 10 mg Medicare Part B payment limit (ASP + 6%): $29.73

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.